Purpose: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab™. We expected to obtain same results as with ReoPro® in improving ischemic cardiac complications in high-risk patients who were about to undergo percutaneous coronary intervention (PCI). Patients and Methods: Patients of 19 -80 years of age with acute coronary syndrome (ACS) who were about to undergo PCI were enrolled. After screehing and confirmation of eligibility, patients were randomly assigned to different groups. Clotinab™ was given to 84 patients (58.7 ± 10.6 years, M: F = 68: 16) and ReoPro® (59.0 ± 10.5 years, M: F = 30: 10) was given to 40 patients before PCI. The primary efficacy endpoint was the onset of major adverse cardiac event (MACE) within 30 days from day 1. The tolerability endpoints were assessed based on bleeding, thrombocytopenia, hange in Hb/Hct, human antichimetric antibody development, and advers events. Results: The nurnber of Clotinab™ patients experiencing MACE was 0 out of 76 per protocol (PP) patients. The MACE rate was 0%, and its 95% exact Cl was [0.00-4.74%]. A major bleeding event developed in 3 patients in the ReoPro® group. The probability of MACE onset in Clotinab™ was estimated to be less than 5%. There was no clinically significant result in tolerability variables. Conclusion: Clotinab™ is an effective and safe medicine in preventing ischemic cardiac complications for high-risk patients who will receive PCI.
All Science Journal Classification (ASJC) codes